RAS病相关肥厚型心肌病患者的猝死风险
这项国际多中心队列研究比较了RAS-HCM与原发性HCM患儿,发现RAS-HCM的10年SCD累积发生率与原发性HCM无差异(4.7% vs 4.2%),但非心律失常性死亡或移植更高(11.0% vs 5.4%),ICD植入率低5倍(6.9% vs 36.6%)。
要点
- RAS-HCM患儿SCD风险与原发性HCM相似,但ICD植入率显著更低。
- RAS-HCM非心律失常性死亡或移植风险更高,主要发生在婴儿期。
- 需加强RAS-HCM风险分层以指导ICD决策,并监测心衰。
核心结论
- RAS-HCM患者非心律失常性死亡或移植发生率高于原发性HCM,但SCD发生率相似,且ICD使用频率更低。
研究设计与样本
- 国际21中心队列研究,纳入表型阳性儿童RAS-HCM患者188例和原发性HCM患者567例。
主要发现
- RAS-HCM诊断中位年龄低于原发性HCM(0.9岁[IQR:0.2-5.0] vs 9.8岁[IQR:2.0-13.9],P<0.001)。
- 首次评估后10年SCD累积发生率RAS-HCM与原发性HCM无差异(4.7% vs 4.2%,P=0.59)。
- 10年非心律失常性死亡或移植累积发生率RAS-HCM更高(11.0% vs 5.4%,P=0.011)。
- 10年ICD植入累积发生率RAS-HCM低5倍(6.9% vs 36.6%,P<0.001)。
- 非心律失常性死亡主要发生于婴儿期,SCD主要发生于青春期。
临床怎么用
- RAS-HCM患者应监测心力衰竭并及时考虑晚期心衰治疗。
- 需更好的风险分层指导RAS-HCM的ICD实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genetic defects in the RAS/mitogen-activated protein kinase pathway are an important cause of hypertrophic cardiomyopathy (RAS-HCM). Unlike primary HCM (P-HCM), the risk of sudden cardiac death (SCD) and long-term survival in RAS-HCM are poorly understood. OBJECTIVES: The study's objective was to compare transplant-free survival, incidence of SCD, and implantable cardioverter-defibrillator (ICD) use between RAS-HCM and P-HCM patients. METHODS: In an international, 21-center cohort study, we analyzed phenotype-positive pediatric RAS-HCM (n = 188) and P-HCM (n = 567) patients. The between-group differences in cumulative incidence of all outcomes from first evaluation were compared using Gray's tests, and age-related hazard of all-cause mortality was determined. RESULTS: RAS-HCM patients had a lower median age at diagnosis compared to P-HCM (0.9 years [IQR: 0.2-5.0 years] vs 9.8 years [IQR: 2.0-13.9 years], respectively) (P < 0.001). The 10-year cumulative incidence of SCD from first evaluation was not different between RAS-HCM and P-HCM (4.7% vs 4.2%, respectively; P = 0.59). The 10-year cumulative incidence of nonarrhythmic deaths or transplant was higher in RAS-HCM compared with P-HCM (11.0% vs 5.4%, respectively; P = 0.011). The 10-year cumulative incidence of ICD insertions, however, was 5-fold lower in RAS-HCM compared with P-HCM (6.9% vs 36.6%; P < 0.001). Nonarrhythmic deaths occurred primarily in infancy and SCD primarily in adolescence. CONCLUSIONS: RAS-HCM was associated with a higher incidence of nonarrhythmic death or transplant but similar incidence of SCD as P-HCM. However, ICDs were used less frequently in RAS-HCM compared to P-HCM. In addition to monitoring for heart failure and timely consideration of advanced heart failure therapies, better risk stratification is needed to guide ICD practices in RAS-HCM.
引用
- Lynch A, Tatangelo M, Ahuja S, et al. Risk of Sudden Death in Patients With RASopathy Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2023. PMID: 36922089. doi:10.1016/j.jacc.2023.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。